

NADH Cytochrome b_5 Reductase and Cytochrome b_5 Catalyze the Microsomal Reduction of Xenobiotic Hydroxylamines and Amidoximes in Humans

Joseph R. Kurian, Sunil U. Bajad, Jackie L. Miller, Nathaniel A. Chin, and Lauren A. Trepanier

Department of Medical Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, Wisconsin

Received June 15, 2004; accepted August 6, 2004

ABSTRACT

Hydroxylamine metabolites, implicated in dose-dependent and idiosyncratic toxicity from arylamine drugs, and amidoximes, used as pro-drugs, are metabolized by an as yet incompletely characterized NADH-dependent microsomal reductase system. We hypothesized that NADH cytochrome b_5 reductase and cytochrome b_5 were responsible for this enzymatic activity in humans. Purified human soluble NADH cytochrome b_5 reductase and cytochrome b_5 , expressed in *Escherichia coli*, efficiently catalyzed the reduction of sulfamethoxazole hydroxylamine, dapsone hydroxylamine, and benzamidoxime, with apparent K_m values similar to those found in human liver microsomes and specific activities (V_{max}) 74 to 235 times higher than in microsomes. Minimal activity was seen with either protein alone, and microsomal protein did not enhance activity

other than additively. All three reduction activities were significantly correlated with immunoreactivity for cytochrome b_5 in individual human liver microsomes. In addition, polyclonal antibodies to both NADH cytochrome b_5 reductase and cytochrome b_5 significantly inhibited reduction activity for sulfamethoxazole hydroxylamine. Finally, fibroblasts from a patient with type II hereditary methemoglobinemia (deficient in NADH cytochrome b_5 reductase) showed virtually no activity for hydroxylamine reduction, compared with normal fibroblasts. These results indicate a novel direct role for NADH cytochrome b_5 reductase and cytochrome b_5 in xenobiotic metabolism and suggest that pharmacogenetic variability in either of these proteins may effect drug reduction capacity.

Hydroxylamine and amidoxime compounds are metabolized in humans by an as yet incompletely characterized NADH-dependent reductase system. Hydroxylamine metabolites have been implicated in dose-dependent and idiosyncratic drug toxicity from sulfamethoxazole, dapsone, procainamide, and other arylamine drugs (Uetrecht, 2002). Amidoximes and other hydroxylated amines have been developed as prodrugs to enhance the absorption of a wide range of antihypertensive, antiprotozoal, and antithrombotic drugs (Weller et al., 1996; Hall et al., 1998; Clement, 2002), and the reduction of these compounds is necessary for drug bioactivation. Thus, the reduction of hydroxylamines and amidoximes has important toxicologic and therapeutic implications.

Xenobiotic hydroxylamines and amidoximes are reduced to

their parent amines by a microsomal, oxygen-insensitive, NADH-dependent enzyme system, variably termed NADH-dependent *N*-hydroxy amine reductase, NADH-benzamidoxime reductase, or NADH-dependent hydroxylamine reductase (NDHR) (Kadlubar and Ziegler, 1974; Cribb et al., 1995; Clement et al., 1998; Trepanier and Miller, 2000). NDHR was originally described in the reduction of *N*-methylhydroxylamine, *N*-hydroxyamphetamine, and related compounds (Kadlubar et al., 1973; Kadlubar and Ziegler, 1974; Yamada et al., 1988). NDHR has more recently been shown to catalyze the reduction of hydroxylamine metabolites of sulfamethoxazole and dapsone (Cribb et al., 1995; Clement et al., 1998), as well as the reduction of *N*-hydroxylated derivatives of benzamidine, debrisoquine, guanabenz, methamphetamine, and pentamidine (Clement, 2002) (Fig. 1).

The complete characterization of NDHR has not been reported in humans, but in the pig, a protein with sequence homology to CYP2D6 has been proposed to be involved in the reduction of hydroxylamines (Clement et al., 1997), along

This work was supported by National Institutes of Health Grant GM 61753. Article, publication date, and citation information can be found at <http://jpet.aspetjournals.org>. doi:10.1124/jpet.104.072389.

ABBREVIATIONS: NDHR, NADH-dependent hydroxylamine reductase; P450, cytochrome P450; cyt b_5 , cytochrome b_5 ; b_5R , NADH cytochrome b_5 reductase; PBS, phosphate-buffered saline; SMX-HA, sulfamethoxazole hydroxylamine; HPLC, high performance liquid chromatography; HSA, human serum albumin; HLM, human liver microsomes.




Fig. 1. Reported substrates of oxygen-insensitive microsomal NDHR.

with NADH cytochrome *b*₅ reductase and cytochrome *b*₅. NADH-dependent hydroxylamine reduction in humans, however, does not correlate with the activities of CYP2D6, nor with the activities of CYP1A2, 2A6, 2C8, 2C9, 2C19, 2E1, 3A4, or 3A5 (Cribb et al., 1995; Lin et al., 1996). In addition, NDHR activity is insensitive to azide and carbon monoxide (Kadlubar et al., 1973; Trepanier and Miller, 2000), which is inconsistent with the involvement of electron transport through P450 in this reaction.

NADH cytochrome *b*₅ reductase (EC 1.6.2.2; diaphorase I; NADH:ferricytochrome *b*₅ oxidoreductase) and cytochrome *b*₅ themselves have all of the biochemical characteristics of NDHR and, therefore, may be capable of directly mediating NADH-dependent hydroxylamine reduction in humans. These proteins, however, have historically been viewed as "helper" enzymes involved in intermediate electron transfer (Porter, 2002) and have not been shown to have a major direct role in xenobiotic metabolism. In this report, we provide evidence that purified human recombinant NADH cytochrome *b*₅ reductase (b5R) and cytochrome *b*₅ (cyt b5) without any other microsomal components are sufficient for the reduction of sulfamethoxazole hydroxylamine, dapsone hydroxylamine, and benzamidoxime to their parent amines/amidines. We show further that the apparent *K*_m values for reduction by the recombinant system are similar to those seen in human liver microsomes and that addition of microsomal protein does not enhance activity more than additively. In addition, hydroxylamine and amidoxime reduction activities correlate with microsomal cyt b5 content, are inhibited by antiserum to either b5R or cyt b5, and are absent in fibroblasts deficient in b5R. We conclude that b5R and cyt b5 together have an important direct role in xenobiotic reduction and further hypothesize that variability in the expression of either of these proteins may have important therapeutic and toxicologic consequences.

Materials and Methods

Expression of Soluble Human NADH b5R. The full-length cDNA of human soluble b5R was kindly provided by Dr. Komei

Shirabe (Oita Medical University, Japan). Initial attempts to purify the protein using DEAE and 5'-AMP-Sepharose column chromatography lead to poor yields, due to weak affinity of b5R for 5'-AMP-Sepharose under a variety of conditions. The cDNA was inserted into an N-terminal histidine tag expression system (pCR T7/NT-TOPO; Invitrogen, Carlsbad, CA) to allow purification from *Escherichia coli* lysate using nickel affinity chromatography. Induction with 1 mM isopropyl β-D-thiogalactopyranoside was performed for 4 h at room temperature to prevent overexpression and compartmentalization of the protein in lipid vacuoles. Stepwise elution of lysate contaminants followed by His-tagged b5R was accomplished with three elution buffers: 20, 100, and 350 mM imidazole, each at pH 8.0 in binding buffer. The eluent was collected in 1-ml fractions, which were tested for purity by gel electrophoresis and subsequent silver staining, for identity using immunoblotting, and for activity using potassium ferricyanide reduction (Arinc and Cakir, 1999). The fractions containing a single 36-kDa band on silver stain were pooled and dialyzed against binding buffer, pH 8.0, through 10,000 mol. wt. cut-off cassettes (Pierce Biotechnology, Rockford, IL) to remove imidazole. The dialyzed sample was again bound to a nickel column and re-purified and pooled as described above. The purified b5R was dialyzed against PBS, pH 7.4, and concentrated to a final protein concentration of 2 to 3 mg/ml using 10,000 mol. wt. cut-off filtration devices (Centricon; Millipore Corporation, Bedford, MA). Purified protein retained maximal activity at 4°C for approximately 3 weeks.

Expression of Soluble Human cyt b5. The full-length cDNA of human soluble cyt b5 (Lloyd et al., 1994), kindly provided by Dr. Grant Mauk (University of British Columbia) was expressed in the pCR T7/CT-TOPO system, using methods as described for b5R, with some modifications. In brief, stepwise elutions using 20, 40, and 100 mM imidazole, each at pH 8.0 in binding buffer, were collected in 1-ml fractions and tested for purity by gel electrophoresis and subsequent silver staining. Identity was verified with immunoblotting. Fractions containing a single 16.5-kDa band on silver stain were pooled, dialyzed, and re-purified as described for b5R. Purified protein retained maximal activity at 4°C for approximately 3 weeks.

Hydroxylamine Reduction by Human b5R and cyt b5. Sulfamethoxazole-hydroxylamine (SMX-HA; Dalton Chemical Laboratories, Toronto, ON, Canada) in 50% dimethyl sulfoxide/3 mM ascorbic acid was incubated at varying concentrations with purified soluble human recombinant b5R and cyt b5. Commercially available cyt b5 protein (PanVera Corp., Madison WI), was used for preliminary experiments; the soluble form of cyt b5, purified to homogeneity as described above, was used for all subsequent experiments. Reactions were performed in PBS, pH 7.4, with 1 mM NADH; glutathione and ascorbic acid (1 mM each) were included to maximally stabilize the SMX-HA against further oxidation (Trepanier and Miller, 2000). The final dimethyl sulfoxide concentration in all reactions was 1.25%. The optimal stoichiometry of b5R/cyt b5 was determined by measuring reduction activity using different ratios of b5R to cyt b5 while keeping the total nanomoles of protein constant (Huang, 1982). Sulfamethoxazole hydroxylamine reduction activities were determined using isocratic HPLC with UV detection as previously described (Trepanier and Miller, 2000). Negative controls included human serum albumin (HSA) or protein purified from sham-transfected *E. coli* and recombinant systems lacking NADH or substrate.

Dapsone hydroxylamine was a gift from Dr. Reginald Frye (School of Pharmacy, University of Pittsburgh). Reduction of dapsone hydroxylamine was determined using HPLC as described for sulfamethoxazole. Retention times for dapsone and its hydroxylamine were 6.6 and 5.2 min, respectively. In addition, the reduction of benzamidoxime [a prototypical oxime substrate also subject to NADH-dependent microsomal reduction (Clement et al., 1997)] to benzamidine was measured using a modification of a previously published HPLC method (Clement et al., 1988). In brief, the mobile phase consisted of water/methanol/phosphoric acid 85%/triethylamine/1-octanesulfonic acid sodium salt (68/32/0.0036/0.0050/0.0012, v/v/v/v/M), with a flow

rate of 1.5 ml/min. UV detection was at 229 nm, with retention times of 13.5 min for benzamidoxime and 15.1 min for benzamidine.

Estimates for apparent K_m and V_{max} of the expressed protein system for the three substrates were determined by nonlinear curve fitting using commercial software (Prism 3; GraphPad Software, Inc., San Diego CA). For comparison of specific activity and apparent K_m values between recombinant and microsomal systems, kinetics were also determined in pooled human liver microsomes (BD Gentest, Woburn, MA).

Immunocorrelation Studies. For preliminary studies, rabbit polyclonal antibody to rat b5R was kindly provided by Dr. Jose Villalba (Universidad de Cordoba, Spain). For subsequent studies, purified human b5R and cyt b5 were used to immunize individual rabbits using standard protocols. Immune rabbit anti-b5R and anti-cyt b5 sera were used to probe immunoblots prepared from microsomal protein (40 μ g) from individual human liver microsomes (Human Biologics International, Scottsdale AZ). Polyvinylidene difluoride membranes (Immobilon-P; Millipore Corporation) were blocked with 2.5% nonfat dry milk in PBS/0.1% Tween-20 and washed with PBS/0.1% Tween-20. Primary antisera were diluted 1:10,000 for immunoblotting; horseradish peroxidase-linked secondary antibody (donkey anti-rabbit IgG; Amersham Biosciences, Inc., Piscataway, NJ) was diluted 1:10,000. An enhanced chemiluminescence system was used for signal detection (Amersham Biosciences, Inc.), and was quantified using a Storm 840 imaging system with ImageQuaNT software (Amersham Biosciences, Inc.). For each of the individual human liver microsome samples, b5R and cyt b5 immunoreactivity were correlated with microsomal reduction of each substrate as determined by HPLC as described above using a correlation z test (Statview; Abacus Concepts, Berkeley, CA).

Immunoinhibition of Reduction. Antisera (150 μ l each) to human b5R and cyt b5 as described above were preincubated with human liver microsomes (0.5 mg) for 30 min at room temperature, followed by quantitation of reduction of sulfamethoxazole hydroxylamine. Preimmune rabbit serum or HSA instead of serum was used as negative controls.

Hydroxylamine Reduction in Fibroblasts Deficient in b5R. Fibroblasts from a patient with type II hereditary methemoglobinemia, a disorder in which systemic b5R activity is deficient or completely lacking, were generously provided by Drs. Wilfried Kugler and Arnulf Pekrun (Universitäts-Kinderklinik, Goettingen, Germany) (Kugler et al., 2001). Normal human dermal fibroblasts were a gift from the laboratory of Drs. Gregory MacEwen and David Vail (University of Wisconsin-Madison). Cells were cultured in Eagle's minimum essential media (without phenol red, calcium, or magnesium; Mediatech Inc., Herndon VA), supplemented with 1 mM sodium pyruvate, 2 mM L-glutamine, 100 IU/ml penicillin, 100 μ g/ml streptomycin, and 0.25 μ g/ml amphotericin, and incubated at 37°C in a humidified atmosphere with 5% CO₂. Cells were harvested with trypsin containing 670 μ M EDTA, washed with medium followed by Hanks' buffer, and resuspended in 15 mM HEPES, pH 7.4. Reduction activity reactions contained 1.5×10^6 cells, along with 500 μ M of SMX-HA. Glutathione and ascorbate (1 mM each) were included in SMX-HA reactions to prevent further oxidation of the hydroxylamine. Cells were incubated at 37°C for 40 min. Reactions were stopped on ice with half the reaction volume of methanol, then filtered through 30-kDa filters (Millipore Corporation) prior to HPLC analysis. Fibroblasts were also subjected to immunoblotting using both α -cyt b5 and α -b5R.

Results

b5R Protein Expression and Purification. Expression of histidine-tagged human soluble b5R in *E. coli* and purification using nickel affinity chromatography yielded an average of 3 to 4 mg of purified protein per liter of culture. A single 36-kDa protein (32-kDa protein plus 4-kDa tag) was

obtained with consistent purity and strong immunoreactivity with anti-b5R antibody (Fig. 2). Preliminary studies showed no difference in activity between tagged and untagged protein (as others have shown; Bewley et al., 2001), and since enterokinase cleavage and processing to remove the His tag resulted in a less pure product (data not shown), all subsequent studies were performed with histidine-tagged protein.

cyt b5 Protein Expression and Purification. Expression and purification of histidine-tagged human soluble cyt b5 yielded an average of 5 mg of purified protein per liter of culture. A single 16.5-kDa protein (12.5-kDa protein plus 4-kDa tag) was obtained with consistent purity and strong immunoreactivity with anti-cyt b5 antibody (Fig. 3).

Reduction of Hydroxylamine and Amidoxime Substrates. Expressed b5R and cyt b5 catalyzed the efficient reduction of sulfamethoxazole hydroxylamine (500 μ M), at rates 160 times greater than pooled human liver microsomes (HLM; Fig. 4). No activity was seen with protein purified with sham-transformed *E. coli* or in the absence of NADH, and minimal activity was observed with either b5R or cyt b5 alone. No enhancement of activity other than an additive effect was seen with the addition of 10, 100, 300, or 1000 μ g of pooled human liver microsomes to the recombinant system (Fig. 5).

The optimal stoichiometry of cyt b5 to b5R was between 8:1 and 10:1 as determined by a Job plot (Huang, 1982) (data not shown). The kinetics of sulfamethoxazole hydroxylamine reduction in the expressed system (Fig. 6) and in HLM were each fit to a one-site model with similar apparent K_m values (Table 1). Dapsone hydroxylamine and benzamidoxime were also reduced by the recombinant system with 163 and 74




Fig. 2. Purified human soluble cytochrome b_5 reductase. Panel A: lane 1, marker; lane 2, *E. coli* lysate (50 μ g) containing expressed human soluble NADH cytochrome b_5 reductase; lane 3, purified b5R (25 μ g), as purified by an N-terminal histidine tag expression system and nickel affinity chromatography; 4 to 20% polyacrylamide gel with Coomassie stain. Panel B: purified cytochrome b_5 reductase (as shown in panel A), immunoblotted with rabbit anti-human b5R antisera. The 36-kDa molecular weight reflects the 32-kDa soluble protein with a 4-kDa histidine tag.




Fig. 3. Purified human soluble cytochrome b_5 . Panel A: lane 1, marker; lane 2, *E. coli* lysate (50 μ g) containing expressed human soluble cytochrome b_5 ; lane 3, purified cytochrome b_5 (25 μ g), as purified by a C-terminal histidine tag expression system and nickel affinity chromatography; 4 to 20% polyacrylamide gel with Coomassie stain. Panel B: purified cytochrome b_5 (as shown in panel A), immunoblotted with rabbit anti-human cytochrome b_5 antiserum. The 16.5-kDa molecular weight reflects the 12.5-kDa soluble protein with a 4-kDa histidine tag.




Fig. 4. Specific activity for reduction of SMX-HA is 160-fold higher by expressed b5R with cytochrome b_5 (10:1 stoichiometry, cyt b5/b5R), compared with pooled HLM (0.5 mg). Negative controls include b5R alone, cyt b5 alone, and protein purified from sham-transformed *E. coli*. Reactions included SMX-HA (500 μ M) with 1 mM NADH, glutathione, and ascorbate, in PBS, pH 7.4. Data are expressed as mean \pm S.D. for two separate experiments each performed in duplicate.

times higher specific activities, respectively, and similar apparent K_m values for each substrate compared with HLM.

Immunocorrelation. Microsomal b5R content (as measured by immunoreactivity to α -b5R) did not correlate with SMX-HA reduction activity (500 μ M substrate) in 27 individ-




Fig. 5. Activity for reduction of SMX-HA (500 μ M) by the recombinant system (Recomb; b5R and cyt b5) compared with the recombinant system plus pooled HLM (0.1 mg) is not more than additive. Note that activity is expressed per minute and is not normalized to milligrams of protein. All reactions are as described in Fig. 4; similar results were seen with 0.01, 0.3, and 1.0 mg of additional microsomal protein.




Fig. 6. Velocity versus substrate concentrations for reduction of SMX-HA by purified human recombinant cytochrome b_5 and NADH cytochrome b_5 reductase (optimal 10:1 stoichiometry) in PBS, pH 7.4, with 1 mM NADH.

ual human liver microsomes (Fig. 7A); however, b5R content in these 27 commercially available samples only differed by 2.2-fold. On the other hand, microsomal cyt b5 content (as measured by immunoreactivity to α -cyt b5) correlated strongly with SMX-HA reduction activity in 19 individual human liver microsomes. ($r = 0.75$; $P = 0.0001$; Fig. 7B) with 9.3-fold variability in cyt b5 immunoreactivity found in this small sample. In addition, microsomal cyt b5 content also correlated with benzamidoxime reduction ($r = 0.64$; $P = 0.025$; Fig. 8) and with dapsone hydroxylamine reduction ($r =$

TABLE 1

Kinetic data for the reduction of two hydroxylamines (HA) and an amidoxime by human recombinant b5R and cyt b5 compared with that seen in pooled HLM

All reactions were performed in PBS, pH 7.4, with 1 mM NADH, under conditions approximating linear kinetics. Velocity data are expressed in nanomoles per total milligrams of protein per minute. Data represent two to three experiments performed in duplicate for each condition, and are given as means \pm S.E.

Substrate	Apparent K_m (μ M)		V_{max} (nmol/mg/min)	
	HLM	b5R/cyt b5	HLM	b5R/ cyt b5
Sulfamethoxazole-HA	363 \pm 31	392 \pm 45	1.93 \pm 0.07	455 \pm 23
Dapsone-HA	357 \pm 62	395 \pm 95	1.26 \pm 0.09	205 \pm 24
Benzamidoxime	629 \pm 116	515 \pm 149	3.05 \pm 0.36	226 \pm 31




Fig. 7. A, microsomal content of NADH cytochrome b_5 reductase (as measured by immunoreactivity to α -b5R) could not be correlated with SMX-HA reduction activity (500 μ M substrate) in 27 individual human liver microsomes ($r = 0.05$). However, there was only 2.2-fold range in b5R content in these available microsomes. B, microsomal cytochrome b_5 content (as measured by immunoreactivity to α -cytochrome b_5) correlates strongly with SMX-HA reduction activity (500 μ M substrate) in 19 individual human liver microsomes ($r = 0.75$; $P = 0.001$). Activity results are from three experiments each performed in duplicate.

0.90; $P = 0.015$; only 7 individual microsomes were tested because of limited substrate supply).

Immunoinhibition. Antisera to b5R and cyt b5 inhibited SMX-HA reduction in human liver microsomes by 69 and 58% respectively, compared with preimmune serum (Fig. 9). This was comparable with the inhibition of SMX-HA reduction by these antisera in the recombinant b5R/cyt b5 system,




Fig. 8. Microsomal cyt b5 content correlates strongly with benzamidoxime reduction activity (100 μ M benzamidoxime) in 12 individual human liver microsomes ($r = 0.64$; $P = 0.025$). Activity results are from two experiments each performed in duplicate.

with 63 and 51% inhibition, respectively, compared with preimmune serum.

Reduction Activity in b5R-Deficient Fibroblasts. Immunoreactive b5R was present in normal human fibroblasts but was absent, as expected, in fibroblasts from a patient with type II hereditary methemoglobinemia (Fig. 10). Similar cyt b5 content was present in both cell types. Reduction of sulfamethoxazole hydroxylamine was virtually undetectable in the b5R-deficient fibroblasts compared with normal human dermal fibroblasts.

Discussion

NADH cytochrome b_5 reductase is an FAD-containing protein with soluble and membrane-bound forms, each the product of the same gene through alternative promoters and alternative splicing (Tomatsu et al., 1989; Leroux et al., 2001). Both soluble (approximately 32 kDa) and membrane-bound (approximately 35 kDa) forms of b5R have identical catalytic domains and differ only in a hydrophobic domain at the N terminus of the membrane-bound form. This 3-kDa N-terminal sequence is myristoylated and allows insertion of the membrane-bound form into endoplasmic reticulum and outer mitochondrial membranes of somatic cells (Ozols et al., 1984). The hemoprotein cytochrome b_5 is also expressed in soluble and membrane-bound forms, although the hydrophobic anchor of membrane-bound cyt b5 is at the C terminus (Borgese et al., 1993). As for b5R, the microsomal and soluble




Fig. 9. Antisera to b5R and cyt b5 (150 μ l each) significantly inhibited the reduction of sulfamethoxazole hydroxylamine in human liver microsomes (by 69 and 58%, respectively) compared with preimmune serum. This was comparable with inhibition seen with these antibodies toward the purified system containing b5R and cyt b5 (63 and 51% inhibition, respectively; data not shown). Microsomes (500 μ g) or b5R and cyt b5 (20.6 μ g of total protein) were preincubated with antisera for 30 min at room temperature prior to initiation of the reaction. Data shown are the results of two to three experiments each performed in duplicate.




Fig. 10. Activity for hydroxylamine reduction is virtually absent in b5R-deficient fibroblasts. Immunoreactivity to b5R (panel A; 35-kDa protein represents microsomal b5R that predominates in fibroblasts) and cyt b5 (panel B; 17-kDa protein represents microsomal cyt b5) antisera in normal human dermal fibroblasts (lane 1) and fibroblasts derived from a patient with type II hereditary methemoglobinemia [lane 2 (Kugler et al., 2001); 40 μ g of protein loaded in each lane]. Panel C, reduction of sulfamethoxazole hydroxylamine by normal and b5R-deficient fibroblasts.

isoforms of cyt b5 are the product of a single gene (Giordano and Steggles, 1991). Together cyt b5 and b5R mediate electron transfer from NADH to fatty acid desaturases (Oshino et

al., 1971) and P450 oxidases (Hildebrandt and Estabrook, 1971) and, in erythrocytes, play a primary role in the maintenance of hemoglobin in its reduced state (Hultquist and Passon, 1971). In addition, b5R mediates the reduction of the partially oxidized form of ascorbate, ascorbyl free radical, back to ascorbate (Ito et al., 1981; Shirabe et al., 1995).

The results of our studies indicate that b5R and cyt b5 also have a direct role in xenobiotic metabolism. This enzyme complex efficiently catalyzed the reduction of the xenobiotic hydroxylamines of dapsone and sulfamethoxazole, as well as the reduction of the prototypical amidoxime prodrug, benzamidoxime. The apparent K_m values for reduction by the purified system were nearly identical to those found in human liver microsomes, and microsomal activity was inhibited by antibodies to either b5R or cyt b5 to the same degree as the recombinant system. The microsomal content of cyt b5 correlated strongly with both microsomal hydroxylamine and amidoxime reduction, and human dermal fibroblasts that lack b5R (Kugler et al., 2001) showed virtually no activity for the reduction of sulfamethoxazole hydroxylamine. Addition of microsomal protein to the recombinant system did not enhance activity more than additively, suggesting that additional microsomal proteins are not important for optimal activity. These data together provide strong evidence that the enzyme complex of b5R and cyt b5 is responsible for the reduction of hydroxylamines and amidoximes in humans.

The reduction of hydroxylamines and amidoximes represents a novel direct role for this enzyme complex in xenobiotic metabolism. Although b5R has been shown to reduce some chemotherapeutic agents to their cytotoxic forms (Mahmutoglu and Kappus, 1988; Hodnick and Sartorelli, 1993), other reports of direct biotransformation by this enzyme complex are lacking. Clement et al. (1997, 1998) reported that b5R and cyt b5 were cofactors in amidoxime and hydroxylamine reduction; however, they concluded that a third protein of P450 origin was necessary for efficient reduction. Our data are in disagreement with these studies, in that our purified recombinant system containing only b5R, cyt b5, and NADH was capable of efficient and complete reduction of one amidoxime and two hydroxylamine substrates. Some reasons for the differences between our data and previous studies could be the species studied (human for our studies compared with pig in previous studies), the source of enzyme complex (recombinant expression in our studies versus biochemical purification in previous studies) or the pH of the reactions (pH 7.4 in our studies versus pH 6.3 previously). In addition, we found an optimal stoichiometry of 8 to 10:1 for cyt b5/b5R, whereas previous studies used b5R in excess of cyt b5 (Clement et al., 1998).

The optimal stoichiometry of 8 to 10 mol of cytochrome b_5 to 1 mol of b5R for hydroxylamine reduction is interesting, given that the reaction presumably entails two successive single-electron reductions from b5R to cyt b5 (Iyanagi et al., 1984). A 10:1 stoichiometry of cyt b5 to b5R has also been found in native liver microsomes (Yang and Cederbaum, 1996) and may reflect the amount of cyt b5 required to maintain a high turnover rate of b5R for cyt b5 reduction (Meyer et al., 1995; Arinc and Cakir, 1999). Because our recombinant system had an optimal stoichiometry similar to that reported for native liver microsomes, the higher activity seen with the recombinant system was most likely due to enrichment of these two proteins, rather than a difference in

the ratio of cyt b5/b5R content between recombinant and native systems.

We had previously reported a model with two apparent K_m values for the reduction of SMX hydroxylamine by HLM (Trepanier and Miller, 2000); however, this was based upon an Eadie-Hofstee transformation of reactions performed in HEPES buffer. Closer examination of that data revealed an artifact (a hump in the velocity versus substrate concentration curve at low concentrations), which was resolved with a switch to PBS buffer, and which then yielded a single apparent K_m in both HLM and the recombinant system.

Polyclonal antibodies to b5R and cyt b5 inhibited hydroxylamine reduction activity, but not completely (Fig. 9). Although this could indicate the involvement of other proteins in this pathway, it is more likely to reflect the imperfect inhibitory capacity of our antisera, since our antisera inhibited the purified b5R/cyt b5 system to the same incomplete degree (63% inhibition by α -b5R and 51% inhibition by α -cyt b5 toward the purified system). One possible mechanism for incomplete inhibition by our sera toward even the recombinant system is steric interference by antibodies directed toward noninhibitory epitopes, preventing the complete binding of antibodies directed at inhibitory epitopes.

One unexpected finding was the lack of correlation between b5R immunoreactive protein and hydroxylamine reduction activity in individual human liver microsomes (Fig. 7A). This was most likely due to the relatively narrow range of b5R content (only 2.2-fold variability) in the 27 individual human liver microsomes evaluated, since it is clear from the lack of activity in reductase-deficient fibroblasts that b5R is necessary for hydroxylamine reduction. It is possible that sampling a much larger group of individual microsomes would reveal outliers in b5R content that would correlate with reduction activity. It is worth noting that cyt b5 content appears to vary more widely in human livers (9.3-fold in only 19 samples) than does its reductase, and therefore cyt b5 may be a more significant source of pharmacogenetic variability for this pathway.

Markedly decreased to absent b5R expression has been reported in hereditary methemoglobinemia, a rare homozygous recessive disorder in which mutations in the b5R gene lead to deficiencies in either soluble b5R alone (type I methemoglobinemia, associated with persistent cyanosis) or in both soluble and membrane-bound b5R (type II methemoglobinemia, associated with cyanosis and mental retardation) (Leroux et al., 1975; Jaffe, 1986). Subjects heterozygous for this disorder show decreased activity of b5R (Reghis et al., 1983), without clinical cyanosis. In contrast to relatively rare mutations causing hereditary methemoglobinemia, less catastrophic polymorphisms in the b5R gene (*DIA1*) have been observed but have not been well characterized. One genetic polymorphism in *DIA1* (T116S) has been reported in African Americans (Jenkins and Prchal, 1997), and slightly higher mean b5R activities have been observed in African Americans compared with Caucasians (Mansouri and Nandy, 1998), although a causal relationship between these two findings has not been established. Absolute cyt b5 deficiency has been reported very rarely, primarily in association with congenital methemoglobinemia (Giordano et al., 1994). Given that b5R and cyt b5 together catalyze the efficient reduction of hydroxylamines and amidoximes, further work is needed to establish the relationship between polymorphisms in this

system, variability in hydroxylamine and amidoxime metabolism, and therapeutic and toxicologic outcome.

In conclusion, the results of these studies indicate that human recombinant NADH cytochrome b_5 reductase and cytochrome b_5 efficiently reduce hydroxylamines and amidoximes without the need for other proteins and support the conclusion that this enzyme complex comprises the previously reported but poorly characterized NADH-dependent hydroxylamine reductase system.

Acknowledgments

Special thanks to Dr. W. Wallace Cleland and Dr. George Reed (Enzyme Institute, University of Wisconsin-Madison) for helpful discussions regarding enzyme kinetic mechanisms and artifacts; Dr. Komei Shirabe (Medical College of Oita, Japan) for soluble b5R cDNA; Dr. Grant Mauk (University of British Columbia, Vancouver, Canada) for soluble cyt b5 cDNA; Dr. Jose Villalba (Universidad de Cordoba, Spain) for anti-b5R antibody used in initial experiments; Dr. Reginald Frye (School of Pharmacy, University of Pittsburgh) for dapsone hydroxylamine; and Drs. Wilfried Kugler and Arnulf Pekrun (Universitäts-Kinderklinik, Goettingen, Germany) for fibroblasts from a patient with type II hereditary methemoglobinemia.

References

- Arinc E and Cakir D (1999) Simultaneous purification of cytochrome b5 reductase and cytochrome b5 from sheep liver. *Int J Biochem Cell Biol* **31**:345–362.
- Bewley M, Marohnic C, and Barber M (2001) The structure and biochemistry of NADH-dependent cytochrome b5 reductase are now consistent. *Biochemistry* **40**:13574–13582.
- Borgese N, D'Arrigo A, DeSilvestris M, and Pietrini G (1993) NADH cytochrome b5 reductase and cytochrome b5 isoforms as a model for the study of post-translational targeting to the endoplasmic reticulum. *FEBS Lett* **325**:70–75.
- Clement B (2002) Reduction of N-hydroxylated compounds: amidoximes (N-hydroxyamides) as pro-drugs of amides. *Drug Metab Rev* **34**:565–579.
- Clement B, Lomb R, and Moller W (1997) Isolation and characterization of the protein components of the liver microsomal O_2 -insensitive NADH-benzamidoxime reductase. *J Biol Chem* **272**:19615–19620.
- Clement B, Moller W, King RS, Kadlubar FF, and Behrens D (1998) Reduction of hydroxylamines by cytochrome b5, NADH-cytochrome b5 reductase and cytochrome P450, in *5th International ISSX Meeting*; 1998 Oct 25–29; Cairns, Australia. P 183, International Society for the Study of Xenobiotics, Bethesda, MD.
- Clement B, Schmitt S, and Zimmerman M (1988) Enzymatic reduction of benzamidoxime to benzamide. *Arch Pharm (Weinheim)* **321**:955–956.
- Cribb AE, Spielberg SP, and Griffin GP (1995) N4-hydroxylation of sulfamethoxazole by cytochrome P450 of the cytochrome P4502C subfamily and reduction of sulfamethoxazole hydroxylamine in human and rat hepatic microsomes. *Drug Metab Dispos* **23**:406–414.
- Giordano S, Kaftory A, and Steggle A (1994) A splicing mutation in the cytochrome b5 gene from a patient with congenital methemoglobinemia and pseudohemaphroditism. *Hum Genet* **93**:568–570.
- Giordano S and Steggle A (1991) The human liver and reticulocyte cytochrome b5 mRNAs are products from a single gene. *Biochim Biophys Res Commun* **178**:38–44.
- Hall J, Kerrigan J, Ramachandran K, Bender B, Stanko J, Jones S, Patrick D, and Tidwell R (1998) Anti-pneumocystis activities of aromatic diamidoxime prodrugs. *Antimicrob Agents Chemother* **42**:666–674.
- Hildebrandt A and Estabrook R (1971) Evidence for the participation of cytochrome b5 in hepatic microsomal mixed-function oxidation reactions. *Arch Biochem Biophys* **143**:66–79.
- Hodnick W and Sartorelli A (1993) Reductive activation of mitomycin C by NADH: cytochrome b5 reductase. *Cancer Res* **53**:4907–4912.
- Huang C (1982) Determination of binding stoichiometry by the continuous variation method: the Job plot, in *Methods Enzymology*, pp 509–525, Academic Press Inc., New York.
- Hultquist D and Passon P (1971) Catalysis of methaemoglobin reduction by erythrocyte cytochrome b5 and cytochrome b5 reductase. *Nat New Biol* **229**:252–254.
- Ito A, Hayashi S, and Yoshida T (1981) Participation of a cytochrome b5-like hemoprotein of outer mitochondrial membrane (OM cytochrome b) in NADH-semidehydroascorbic acid reductase activity of rat liver. *Biochem Biophys Res Commun* **101**:591–598.
- Iyanagi T, Watanabe S, and Anan K (1984) One-electron oxidation-reduction properties of hepatic NADH-cytochrome b5 reductase. *Biochemistry* **23**:1418–1425.
- Jaffe E (1986) Enzymopenic hereditary methemoglobinemia: a clinical/biochemical classification. *Blood Cells* **12**:81–90.
- Jenkins M and Prchal J (1997) A high-frequency polymorphism of NADH-cytochrome b5 reductase in African-Americans. *Hum Genet* **99**:248–250.
- Kadlubar FF, McKee EM, and Ziegler DM (1973) Reduced pyridine nucleotide-dependent N-hydroxy amine oxidase and reductase activities of hepatic microsomes. *Arch Biochem Biophys* **156**:46–57.
- Kadlubar FF and Ziegler DM (1974) Properties of a NADH-dependent N-hydroxy

- amine reductase isolated from pig liver microsomes. *Arch Biochem Biophys* **162**: 83–92.
- Kugler W, Pekrun A, Laspe P, Erdlenbruch B, and Lakomek M (2001) Molecular basis of recessive congenital methemoglobinemia, Types I and II: exon skipping and three novel missense mutations in the NADH cytochrome b5 reductase (diaphorase 1) gene. *Hum Mutat* **17**:348.
- Leroux A, Junien C, Kaplan J, and Bamberger J (1975) Generalised deficiency of cytochrome b5 reductase in congenital methemoglobinemia. *Nature (Lond)* **258**: 619–620.
- Leroux A, Vieira L, and Kahn A (2001) Transcriptional and translational mechanisms of cytochrome b5 reductase isozyme generation in humans. *Biochem J* **355**:529–535.
- Lin J, Beerkman CE, and Cashman JR (1996) N-oxygenation of primary amines and hydroxylamines and retroreduction of hydroxylamines by adult human liver microsomes and adult flavin-containing monooxygenase 3. *Chem Res Toxicol* **9**:1183–1193.
- Lloyd E, Ferrer J, Funk W, Mauk M, and Mauk A (1994) Recombinant human erythrocyte cytochrome b5. *Biochemistry* **33**:11432–11437.
- Mahmutoglu I and Kappus H (1988) Redox cycling of bleomycin-Fe(III) and DNA degradation by isolated NADH cytochrome b5 reductase: involvement of cytochrome b5. *Mol Pharmacol* **34**:578–583.
- Mansouri A and Nandy I (1998) NADH-methemoglobin reductase (cytochrome b5 reductase) levels in two groups of American blacks and whites. *J Invest Med* **46**:82–86.
- Meyer T, Shirabe K, Yubisui T, Takeshita M, Bes M, Cusanovich M, and Tollin G (1995) Transient kinetics of intracomplex electron transfer in the human cytochrome b5 reductase-cytochrome b5 system: NAD⁺ modulates protein-protein binding and electron transfer. *Arch Biochem Biophys* **318**:457–464.
- Oshino N, Imai Y, and Sato R (1971) A function of cytochrome b5 in fatty acid desaturation by rat liver microsomes. *J Biochem (Tokyo)* **69**:155–167.
- Ozols J, Carr S, and Strittmatter P (1984) Identification of the NH₂-terminal blocking group of NADH cytochrome b₅ reductase as myristic acid and the complete amino acid sequence of the membrane binding domain. *J Biol Chem* **259**:13349–13354.
- Porter T (2002) The roles of cytochrome b₅ in cytochrome P450 reactions. *J Biochem Mol Toxicol* **16**:311–316.
- Reghis A, Troungos C, Lostonlen D, Krishnamoorthy R, and Kaplan J (1983) Characterization of weak alleles at the DIA1 locus (Mustapha 1, Mustapha 2, Mustapha 3) in the Algerian population. *Hum Genet* **64**:173–175.
- Shirabe K, Landi M, Takeshita M, Uziel G, Fedrizzi E, and Borgese N (1995) A novel point mutation in a 3' splice site of the NADH-cytochrome b5 reductase gene results in impaired NADH-dependent ascorbate regeneration in cultured fibroblasts of a patient with Type II hereditary methemoglobinemia. *Am J Hum Genet* **57**:302–310.
- Tomatsu S, Kobayashi Y, Fukumaki Y, Yubisui T, Orii T, and Sakaki Y (1989) The organization and the complete nucleotide sequence of the human NADH-cytochrome b5 reductase gene. *Gene (Amst)* **80**:353–361.
- Trepanier L and Miller J (2000) NADH-dependent reduction of sulphamethoxazole hydroxylamine in dog and human liver microsomes. *Xenobiotica* **30**:1111–1121.
- Uetrecht J (2002) N-oxidation of drugs associated with idiosyncratic drug reactions. *Drug Metab Rev* **34**:651–665.
- Weller T, Alig L, Beresini M, Blackburn B and al E (1996) Orally active fibrinogen receptor antagonists. 2. Amidoximes as prodrugs of amidines. *J Med Chem* **39**: 3139–3147.
- Yamada H, Baba T, Oguri K, and Yoshimura H (1988) Enzymic reduction of N-hydroxyamphetamine: the role of electron transfer system containing cytochrome b5. *Biochem Pharmacol* **37**:368–370.
- Yang M-X and Cederbaum A (1996) Interaction of ferric complexes with NADH-cytochrome b5 reductase and cytochrome b5: lipid peroxidation, H₂O₂ generation and ferric reduction. *Arch Biochem Biophys* **331**:69–78.

Address correspondence to: Dr. Lauren Trepanier, Department of Medical Sciences, University of Wisconsin-Madison, School of Veterinary Medicine, 2015 Linden Drive, Madison, WI 53706. E-mail: latrepanier@svm.vetmed.wisc.edu
